WO1996018732A9 - Inhibition specifique des sequences de la synthese de l'adn a l'aide d'oligonucleotides formant des triplex - Google Patents
Inhibition specifique des sequences de la synthese de l'adn a l'aide d'oligonucleotides formant des triplexInfo
- Publication number
- WO1996018732A9 WO1996018732A9 PCT/US1995/016368 US9516368W WO9618732A9 WO 1996018732 A9 WO1996018732 A9 WO 1996018732A9 US 9516368 W US9516368 W US 9516368W WO 9618732 A9 WO9618732 A9 WO 9618732A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- triplex
- strand
- oligonucleotide
- polymerase
- Prior art date
Links
- 229920003013 deoxyribonucleic acid Polymers 0.000 title claims abstract description 175
- 229920000272 Oligonucleotide Polymers 0.000 title claims abstract description 99
- 230000015572 biosynthetic process Effects 0.000 title abstract description 66
- 238000003786 synthesis reaction Methods 0.000 title abstract description 21
- 230000002194 synthesizing Effects 0.000 title abstract description 21
- 230000002401 inhibitory effect Effects 0.000 title description 23
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000000338 in vitro Methods 0.000 claims abstract description 13
- 230000000903 blocking Effects 0.000 claims abstract description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 69
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 40
- 101700011961 DPOM Proteins 0.000 claims description 35
- 101710029649 MDV043 Proteins 0.000 claims description 35
- 101700061424 POLB Proteins 0.000 claims description 35
- 101700054624 RF1 Proteins 0.000 claims description 35
- 230000035772 mutation Effects 0.000 claims description 28
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 26
- 239000011777 magnesium Substances 0.000 claims description 17
- 108010006785 Taq Polymerase Proteins 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 5
- 230000001264 neutralization Effects 0.000 claims description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 101710033916 NRAS Proteins 0.000 claims description 3
- 102100001119 NRAS Human genes 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 238000000137 annealing Methods 0.000 claims description 2
- 230000000813 microbial Effects 0.000 claims description 2
- 230000000379 polymerizing Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 101710028401 gene 5 Proteins 0.000 abstract description 19
- 108010014303 DNA-Directed DNA Polymerase Proteins 0.000 abstract description 17
- 102000016928 DNA-Directed DNA Polymerase Human genes 0.000 abstract description 17
- 108009000097 DNA Replication Proteins 0.000 abstract description 10
- 230000004543 DNA replication Effects 0.000 abstract description 10
- 238000006467 substitution reaction Methods 0.000 abstract description 10
- 101710030546 2.5 Proteins 0.000 abstract description 6
- 101710031367 gV-1 Proteins 0.000 abstract description 6
- 101700041333 C1 Proteins 0.000 abstract description 3
- 101710002785 WIGBRp0010 Proteins 0.000 abstract description 3
- 101700030147 rep Proteins 0.000 abstract description 3
- 101700021040 repB Proteins 0.000 abstract description 3
- 101710002782 repF Proteins 0.000 abstract description 3
- 238000005755 formation reaction Methods 0.000 description 46
- 238000003752 polymerase chain reaction Methods 0.000 description 26
- 210000004027 cells Anatomy 0.000 description 19
- 238000006073 displacement reaction Methods 0.000 description 16
- 108020004532 RAS Proteins 0.000 description 15
- 108020001180 rasD Proteins 0.000 description 15
- 229920002605 Triple-stranded DNA Polymers 0.000 description 14
- 101700071170 LEF-3 Proteins 0.000 description 13
- 101700009501 SSB Proteins 0.000 description 13
- 101700040489 SSB2 Proteins 0.000 description 13
- 101700058838 SSBP1 Proteins 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 101700016657 ssb1 Proteins 0.000 description 13
- 101700008322 ssbF Proteins 0.000 description 13
- 235000019527 sweetened beverage Nutrition 0.000 description 13
- 108020004682 Single-Stranded DNA Proteins 0.000 description 12
- 229910001425 magnesium ion Inorganic materials 0.000 description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N 5-Methyluracil Natural products CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000000875 corresponding Effects 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 238000002372 labelling Methods 0.000 description 9
- 238000001712 DNA sequencing Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- YZHUMGUJCQRKBT-UHFFFAOYSA-M Sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 5
- 101710021645 E. coli ssb Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000006011 modification reaction Methods 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 229920002759 Circular DNA Polymers 0.000 description 4
- 108020004638 Circular DNA Proteins 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 230000000977 initiatory Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002103 transcriptional Effects 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 3
- 229940104302 Cytosine Drugs 0.000 description 3
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 108010010677 Phosphodiesterase I Proteins 0.000 description 3
- 102000001218 Rec A Recombinases Human genes 0.000 description 3
- 108010055016 Rec A Recombinases Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 101710004466 rgy Proteins 0.000 description 3
- 101710030364 rgy1 Proteins 0.000 description 3
- 101710030359 rgy2 Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002142 suicide Effects 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 101710036216 ATEG_03556 Proteins 0.000 description 2
- 229960000643 Adenine Drugs 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 241000283725 Bos Species 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 101700008821 EXO Proteins 0.000 description 2
- 101700083023 EXRN Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 102100015262 MYC Human genes 0.000 description 2
- 101710003000 ORF1/ORF2 Proteins 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 101700030467 Pol Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000002759 chromosomal Effects 0.000 description 2
- 230000001447 compensatory Effects 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000001965 increased Effects 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007524 negative regulation of DNA replication Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000003362 replicative Effects 0.000 description 2
- 230000000754 repressing Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 108091006090 transcriptional activators Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 1
- KBRISHLGLPXESO-UHFFFAOYSA-N 7H-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 KBRISHLGLPXESO-UHFFFAOYSA-N 0.000 description 1
- 206010049460 Abasia Diseases 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M Caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008909 Chronic hepatitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 108090000133 DNA Helicases Proteins 0.000 description 1
- 102000003844 DNA Helicases Human genes 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101710017531 H4C15 Proteins 0.000 description 1
- 101710007269 H4C7 Proteins 0.000 description 1
- 102100007442 H4C7 Human genes 0.000 description 1
- 101700032126 H4Y Proteins 0.000 description 1
- 101710007262 HHF2 Proteins 0.000 description 1
- 101710033925 HRAS Proteins 0.000 description 1
- 102100009283 HRAS Human genes 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- 101710033922 KRAS Proteins 0.000 description 1
- 102100009279 KRAS Human genes 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 102100016958 NCKAP5 Human genes 0.000 description 1
- 101710036971 NCKAP5 Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- LRMQCJCMKQSEJD-UHFFFAOYSA-N Oligo B Polymers O1C(N2C3=NC=NC(N)=C3N=C2)C(OC)C(OC(=O)C=2C=C3C4(OC(=O)C3=CC=2)C2=CC=C(O)C=C2OC2=CC(O)=CC=C24)C1COP(O)(=O)OC1C(C(O2)N3C(N=C(N)C(C)=C3)=O)OCC12COP(O)(=O)OC(C1OC)C(COP(O)(=O)OC2C3(COP(O)(=O)OC4C(C(OC4COP(O)(=O)OC4C(C(OC4COP(O)(=O)OC4C(C(OC4COP(O)(=O)OC4C5(COP(O)(=O)OC6C(C(OC6COP(O)(=O)OC6C7(COP(O)(=O)OC8C(C(OC8COP(O)(=O)OC8C9(CO)COC8C(O9)N8C(N=C(N)C(C)=C8)=O)N8C(NC(=O)C=C8)=O)OC)COC6C(O7)N6C(N=C(N)C(C)=C6)=O)N6C(N=C(N)C=C6)=O)OC)COC4C(O5)N4C(N=C(N)C(C)=C4)=O)N4C5=NC=NC(N)=C5N=C4)OC)N4C5=C(C(NC(N)=N5)=O)N=C4)OC)N4C5=C(C(NC(N)=N5)=O)N=C4)OC)COC2C(O3)N2C(N=C(N)C(C)=C2)=O)OC1N1C=CC(=O)NC1=O LRMQCJCMKQSEJD-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 102000017006 Proto-Oncogene Protein c-ets-2 Human genes 0.000 description 1
- 108010014644 Proto-Oncogene Protein c-ets-2 Proteins 0.000 description 1
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010038997 Retroviral infection Diseases 0.000 description 1
- 101700084441 SFR2 Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040882 Skin lesion Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 230000002457 bidirectional Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229940098124 cesium chloride Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-J dATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-J 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 102000018146 globin family Human genes 0.000 description 1
- 108060003196 globin family Proteins 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 239000003014 ion exchange membrane Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229920001894 non-coding RNA Polymers 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003711 photoprotective Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 150000003139 primary aliphatic amines Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000031267 regulation of DNA replication Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000001718 repressive Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 108040002588 retroviral strand transfer activity proteins Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229920002973 ribosomal RNA Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000035892 strand transfer Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006091 transcriptional repressors Proteins 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 101700044572 virE2 Proteins 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Definitions
- Inhibition of DNA replication is effected by use of specific oligonucleotides that form DNA or DNA-RNA triplexes and block polymerase action.
- Production of DNA or DNA-RNA triplexes at specific DNA targets provides a method to control genetic effects more effectively and more extensively in vivo and in vitro than methods directed to control of gene products or gene transcription.
- DNA polymerases including E.coli Pol I, thermophilic Vent polymerase, DNA polymerases of phages T5 and f29, and chemically or genetically modified T7 DNA polymerase (Sequenase ® ), are able to displace the non-template DNA strand in the course of DNA synthesis without the assistance of energy-driven helicases and other proteins (reviewed in Kornberg and Baker, 1992).
- the role of displaced strand overhangs in genetic recombination is discussed in Lundquist and Olivera (1982).
- An interesting structural consequence of strand displacement that the displaced strand folds back, forming an intramolecular triplex downstream of the replication fork, has not been reported.
- triplexes include two purine and one pyrimidine strand (*H-DNA) (Kohwi and Kohwi-Shegematsu, 1988; Bernues et aL, 1989, 1990).
- *H-DNA pyrimidine strand
- the orientation of the two chemically similar strands is antiparallel, and free energy from DNA supercoiling is required for triplex extrusion.
- Conditions of DNA polymerization in vitro are close to optimal for the formation of * H-DNA. Therefore, when DNA polymerase encounters a potential triplex-forming DNA sequence, the displacement of the purine-rich strand leads to triplex formation.
- the strand orientation in this case will be antiparallel by definition, and DNA-polymerase driven strand overhang formation might efficiently substitute for DNA supercoiling.
- H motifs may account for termination of replication in vivo.
- Polyomavirus DNA integrates in a particular chromosomal site (Mendelsohn et al., 1982), and treatment of the cells with mitomycin C leads to the amplification of virus DNA and adjacent cellular sequences (Baran et al., 1987).
- the boundary of the amplified DNA segment lies within a homopurine-homopyrimidine stretch d(G-A) 27 /d(T-C), 7 . It was suggested that this DNA motif could be a natural replication terminator. Supporting this hypothesis, this motif, when cloned into SV40 DNA adjacent to the origin of replication, paused a replication fork progression causing slower viral growth (Rao et al., 1988).
- the dhfr- ocus is amplified up to 1000 times in methotrexate resistant Chinese hamster cells due to the activity of the strong bidirectional replication origin (Milbrandt et al., 1981).
- d(G) ⁇ l d(A-G) 27I is located 2 kb 3' to the origin of replication (Caddie et al., 1990). This cluster was cloned in the replication vector pSV011 , and the efficiency of episome replication was studied by different approaches.
- TFOs Triplex-forming oligonucleotides interact specifically with homopurine-homopyrimidine sequences in genomic DNA (Le-Doan ef al., 1987; Moser and Dervan, 1987; Lyamichev ef al., 1988). TFOs are usually homopurine or homopyrimidine sequences representing mirror images of chemically similar strands in target DNAs (Mirkin et al., 1987; Beal and Dervan, 1991).
- Homopyrimidine oligonucleotides form stable triplexes und ⁇ r acidic pH (Lyamichev ef al., 1988), a requirement which may be somewhat overcome by methylation of cytosines or by the presence of polyamines (Maher et al., 1989; Hampel et al., 1991). Homopurine oligonucleotides form triplexes under physiological pH in the presence of bivalent cations (Malkov ef al., 1993 and references therein).
- Canonical components of the pyrimidine/purine/pyrimidine (YR.Y) triplexes are CG.C* and TA.T base triads (Felsenfeld ef al., 1957; Morgan and Wells, 1968), while orthodox pyrimidine/purine/purine (YR.R) triplexes consist of CG.G and TA.A triads (Kohwi and Kohwi-Shigematsu, 1988; Bernues ef al., 1989). In the latter case, however, thymines may also be incorporated in the otherwise homopurine strand of the TFO opposite adenines in the target sequence, thus forming TA.T triads (Beal and Dervan, 1991).
- TFOs bind to DNA in a highly sequence specific manner recognizing, for example, unique sites in the yeast (Strobel and Dervan, 1990) and human (Strobel et al., 1991) chromosomes.
- oligonucleotide-directed triplex formation for targeting genetic processes have focused on control of transcription.
- Triplex-forming oligonucleotides have been reported as artificial repressors preventing the binding of transcriptional regulators. Transcription was affected by triplex formation in the human c-myc promoter (Coon ⁇ y ef al., 1988; Postel ef al., 1991) and for the methallothionein gene promoter. In the latter case, a homopyrimidine oligonucleotide formed a triplex with the upstream portion of the promoter preventing the binding of the transcriptional activator Sp1 (Maher ef al., 1992). This in turn drastically reduced the promoter's activation in a cell-free transcription system (Maher et al., 1992).
- a triplex-forming oligonucleotide-intercalator conjugate was shown to act as a transcriptional repressor of the interleukin-2 receptor gene both in vitro and in vivo (Grigoriev ef al., 1992, 1993). Repression was due to the fact that the formation of a triplex additionally stabilized by cross linking to target DNA efficiently prevented the binding of the transcriptional activator NFkB. Different mechanisms of transcriptional inhibition have been also revealed.
- triplex formation may inhibit all stages of the transcriptional cycle: formation of active promoter complex, initiation, and elongation.
- An aspect of the invention is a method for blocking replication of a target DNA by a specifically designed oligonucleotide from a template DNA strand.
- the method comprises bringing an oligonucleotide into contact with said DNA, thereby forming a triplex structure that precludes replication of the DNA.
- the triplex structure prevents the replication fork formed by a polymerase from proceeding past a sequence in the DNA target.
- the method blocks polymerization of a DNA strand by contacting an oligo ⁇ nucleotide with a template to form a triplex DNA structure at a specific target nucleotide sequence.
- the triplex structure blocks polymerization downstream of the sequence.
- oligonucleotide forms a triplex strand configuration of pyrimidine/purine/purine. Replication of a target DNA strand occurs in vitro at a neutral pH and a high concentration of Mg 2 * and is effected by a polymerase which is selected from the group that includes Sequenase ® T7 DNA polymerase, Taq polymerase, Vent polymerase, and E.coli Pol I.
- the invention also relates a triplex-forming oligonucleotide that has a nucleotide sequence having mirror symmetry of G clusters, and is at least 12 bases in length.
- the mirror symmetry of G clusters is selected from a mirror image of a homopurine strand with guanine (G) and adenine (A) residues.
- G guanine
- A adenine
- an oligonucleotide wherein the G residues are mirror images of guanine (G) in the homopurine strand, and intervening regions have thymines (Ts) which reflect As in the homopurine strand.
- the target DNA may be in either a non-transcribed or a transcribed region. Because transcribed regions tend to be relatively small, blockage of non- transcribed regions is an advantage of the present invention. Alternate strand oligonucleotides and those incorporating non-natural bases may be used to block replication.
- a use for the oligonucleotide composition of the present invention is in a method for detecting a mutation in a DNA template for an oncogene.
- the method comprises:
- the polymerase chain reaction conditions include: (a) use of the Stoffel fragment of Taq polymerase which lacks exonuclease activity and is active at high magnesium concentrations; (b) a high (10 mM) magnesium concentration which makes DNA triplexes stable at elevated temperatures; and (c) an optimal temperature for the reaction which depends on the
- the method is suitable for detection of an oncogene which is a member of the ras oncogene family. In particular mutations in codon 12 or 13 of a ras oncogene are sought.
- Important therapeutic aspects of the invention include a method for blocking elongation of a target DNA strand by polymerization of a DNA template in vivo by providing an oligonucleotide capable of forming a triplex with the target DNA strand under polymerizing conditions and providing the conditions for polymerization of the template.
- the DNA includes mammalian DNA, for example, human DNA.
- oligonucleo ⁇ tide With regard to attack by the oligonucleo ⁇ tide on infectious microorganisms, the invention is suitable for use against the Herpes Simplex Virus 1 and the Hepatitis B Virus.
- Specific oligonucleotides are related herein for blocking the replication of these viruses.
- oligonucleotides used for human therapy are: (1) easily synthesized and can be prepared in bulk; (2) may be made stable in vivo; (3) are capable of entering a target cell; (4) are retained by the target cell long enough to inhibit replication, thereby precluding cell division; and (5) show specificity of action.
- oligonucleotides may be synthesized by methods known to those of skill in the art or produced within a cell, for example, by recombinant technology. These intracellular oligonucleotides can inhibit DNA replication within the cell, or can be extracted for use elsewhere. Delivery of oligonucleotides to a target site within an organism is accomplished by one of the following or an equivalent method; direct intravenous injection of free oligonucleotides or oligonucleotides delivered by use of liposomes, and other means of delivering oligonucleotides to a target in an organism.
- Another aspect of the invention is a method for treating a microbial infection in an organism.
- the method includes providing a composition comprising triplex-forming oligonucleotides directed toward a specific sequence in the agent causing the infection, said oligonucleotides in a pharmacologically acceptable carrier and delivering an effective amount of the composition to the organism.
- Methods and compositions designed to halt DNA replication at defined chromosomal sequences by means of triplex-forming oligonucleotides are aspects of the invention. Elongation of DNA polymerization is blocked at specific sequences by triplex-forming oligonucleotides that provide highly sequence specific recognition of target DNA. Such artificial terminators have therapeutic potential because they can prevent deleterious genes from replicating.
- An advantage of this method is a permanent inhibition of the propagation of specific gene segments. A consequence of this inhibition is repression of the growth of specific cell types, including cancer cells and infectious agents. Regulation of DNA replication may also be elucidated using these methods and compositions.
- oligonucleotides form triplexes of single-or double-strand DNA at homopurine-homopyrimidine targets.
- targets are homopurine-homopyridine sequences in eukaryotic gene promoters as exemplified below:
- Drosophila hsp2 6 AGAGAGAAGAGAAGAGAGAGA These complexes almost completely block in vitro DNA synthesis by all DNA polymerases studied, including Sequenase ® , Taq, Vent, Pol and the like. A similar phenomenon occurs when DNA polymerases are supplemented with accessory replication proteins, including SSB protein. Replication blockage is highly sequence-specific and even one or two point substitutions within either the target sequence or the oligonucleotide abolish the effect. This presents an opportunity for sequence-specific blocking of DNA replication in
- TFOs are agents for blocking DNA replication in vivo in a site-specific manner.
- targets for TFOs within eukaryotic genes specifically in introns and promoter regions. These targets may be utilized to block elongation of replication.
- eukaryotic origins of replication located in the human c- yc and histone H4 genes, hamster dhfr gene, yeast chromosome III, Stylonihia tubulin gene, and the like contain the consensus Pur element: GGNNGAGGGAGAPuPuPuPu
- Triplex Three strands of DNA or a DNA-RNA combination linked by hydrogen bonding: Watson-Crick and Hoogsteen bonding.
- H-Motifs Perfect or near perfect homopurine - homopyrimidine mirror repeats.
- H-DNA An intramolecular triplex formed by two pyrimidine and one purine DNA strand (formed under mild acidic conditions). * H-DNA: An intramolecular triplex formed by two purine and one pyrimidine strand (formed under neutral pH in the presence of bivalent cations).
- FIG. 1 Conformational suicide within H motifs during DNA polymerization.
- the diamond shows the original nick in the double-helical template providing a 3 '-OH end for DNA polymerase; the black boxes represent two halves of a hypothetical homopurine- homopyrimidine mirror repeat involved in the formation of an intramolecular triplex; the striated arrow shows the newly synthesized DNA chain.
- FIG. 2 Construction and sequencing strategy of open circular DNA templates.
- the black box represents an H motif
- the striated arrow shows newly synthesized labeled DNA.
- FIG. 3 Short triplexes within single stranded templates.
- FIG. 4 DNA templates containing short double- and triple-helical stretches. Hoogsteen pairs are shown by asterisks (.), 3' amino groups are shown by pound symbols (#). Arrows correspond to the "reverse" primer.
- FIG. 5 DNA templates containing polymerization primers within triple-helical stretches. Hoogsteen pairs are shown by asterisks (.), 3 *" amino groups are shown by pound symbols (#). Either homopyrimidine (A-C) or homopurine (D-F) oligonucleotides served as primers. These primers were added to the templates either alone to form Watson-Crick duplexes (A, D), or together with purine-rich TFOs (B, E) forming intermolecular triplexes consisting of CG.G and TA.T triads, or in the presence of mutant TFOs lacking triplex-forming ability due to G-to-T substitutions (C, F). The primer is a component of a triplex in both B and E; in B it is involved only in Watson-Crick base pairing, while in E it participates in Watson-Crick and Hoogsteen base pairing.
- A-C homopyrimidine
- D-F homopurine oligonucleot
- FIG. 6. Inhibition of PCR .by TFO.
- Solid lines represent template strands; solid arrows represent PCR primers; dashed arrows represent newly synthesized DNA chains, points represent Watson - Crick hydrogen bonds; asterisks represent Hoogsteen hydrogen bonds; the ponds symbol represents the 3'amino group.
- FIG. 7 Partial nucleotide sequences for three members of the ras gene family. Codons 12 and 13 where most of the tumorigenic mutations occurs are outlined.
- FIG. 8 Scheme of TFO-caused PCR inhibition of the wild-type human N-ras gene. Mutations within GGT repeats that cause oncogene activation make triplex formation unfavorable and reverse PCR inhibition.
- DNA polymerase causes self-replication termination.
- conformational suicide provides a novel way to target DNA polymerases at specific sequences using triplex-forming oligonucleo ⁇ tides.
- mutations which destroy the triplex potential of triplex- forming sequences prevent termination of polymerases such as T7 DNA polymerase (Sequenase) on open circular DNAs, whereas compensatory mutations which restored triplex potential also restored termination.
- polymerases such as T7 DNA polymerase (Sequenase)
- TFOs Triplex-forming oligonucleotides
- Sequenase® and thermophilic Taq and Vent polymerases The termination rate depends on the fine structure of a triplex, as well as on ambient conditions such as the temperature and the concentration of magnesium ions. Inhibition of DNA synthesis was observed not only when triplexes blocked the path of DNA polymerase, but also when a polymerization primer was involved in triplex formation.
- Double mutant I has two G-to-T substitutions in the 5 '-half of the purine-rich strand, while double mutant II has two symmetrical G-to-A substitutions in its 3'-half. In both cases, the mirror
- CAA pyrimidine-rich strand to CAA (Dayn et al., 1992). Therefore, CAA was used to test triplex formation in all four cases. Plasmids were CAA-modified in the presence of bivalent cations (Mg- + or Zn 8+ ) followed by restriction digestion and end-labeling. Samples were then treated with either formic acid (purine reaction) or hydrazine in high salt (cytosine reaction) followed by piperidine cleavage and sequencing gel-electrophoresis.
- bivalent cations Mg- + or Zn 8+
- CAA modification of cytosines leads to the enhancement of corresponding bands on the cytosine ladder and appearance of new bands on a purine ladder, while the adenine modification enhances corresponding bands in a purine ladder and leads to the appearance of new bands in the cytosine ladder (Kohwi and Kohwi-Shigematsu, 1988).
- the wild type sequence Only for the wild type sequence is the 3'-part of the pyrimidine-rich strand CAA-reactive in the presence of magnesium ions. Thus, under these conditions only this sequence adopts an *H conformation. In the presence of zinc ions, however, both the wild type
- the quadruple mutants are chemically hyperreactive.
- the double mutants show no CAA-reactivity under any conditions studied.
- both wild type and quadruple mutant sequences may adopt the *H-conformation in the presence of bivalent cations, while the double
- the wild type sequence has a better *H forming ability because it forms a triplex under all conditions tested and demonstrates a more prominent modification pattern than the quadruple mutant in the presence of zinc ions.
- the difference between the two sequences in cation requirements is most probably due to the difference in their AT-content.
- the quadruple mutant was derived from the wild type by four GC-to-AT substitutions and is, therefore, significantly more AT-rich.
- *H-DNA formed by d(G) n d(C) n sequences is stabilized by Mg 2+ , but the same structure formed by d(G-A) n d(T-C) n stretches is stable only in the presence of Zn 2+ .
- Double-helical DNA templates containing a single-stranded nick (serving as a primer) was studied.
- the strategy for obtaining such templates is outlined in FIG. 2.
- Single-stranded circular phage DNA containing either the purine-rich or the pyrimidine-rich strand of inserts from E.coli cells carrying pBLUESCRIPT plasmids as described in Materials and Methods was recovered. Then RecA-mediated strand transfer to these
- DNA sequencing reactions were conducted on open circular templates as described in the Materials and Methods.
- DNA samples were digested with Sst I restriction enzyme after polymerization (the Sst I site could only be restored in the course of DNA synthesis).
- Sst I site could only be restored in the course of DNA synthesis.
- the most striking results were obtained for the "wild type sequence," an arbitrary designation for the synthetic sequence from which "mutations" were generated.
- the pyrimidine-rich strand served as a template, almost complete termination of polymerization at the middle of this sequence was observed.
- the purine-rich strand of the same sequence served as a template, no termination was observed. This remarkable difference between the two strands may be explained through triplex formation.
- the purine-rich strand is displaced and may form a triplex under polymerization conditions, while a displaced pyrimidine-rich strand cannot form a triplex, because pyrimidine-purine-pyrimidine triplexes are stable only under acidic pH.
- a DNA sequencing protocol was used to locate termination sites at a nucleotide base level. Control experiments showed that termination is not specific for dideoxyNTP substrates. The same extent of termination was observed when "normal" dNTP substrates were used in the experiment. Studies of the mutated sequences provided additional support for this interpretation. For both double mutants, no termination of DNA polymerase was observed even when the pyrimidine-rich strand served as a template. With the quadruple mutant prominent termination was
- the displacement of the purine-rich strand provides a sufficiently high local concentration of the third strand at the double-helical
- oligodeoxynucleotides corresponding to the 5'-part of the purine-rich strand of the wild-type (dGGGTGGTGGGTGGGG) or double mutant I (dGGGTGGTTGGTGTGG) were synthesized. Each of these oligonucleotides was then incubated in Sequenase® buffer with linear double-stranded DNAs containing either the wild type or the quadruple mutant sequences.
- Sequenase® buffer with linear double-stranded DNAs containing either the wild type or the quadruple mutant sequences.
- Four oligonucleotide-to- template combinations corresponding to all the triplexes formed by all our sequences were available.
- DNA mixtures were UV irradiated and treated with piperidine followed by sequencing gel-electrophoresis (in all the cases the pyrimidine-rich strands of double-stranded DNAs were end-labeled).
- Photo protection appeared in the pyrimidine strand in two cases: (i) both oligonucleotide and template are of the wild type, and (ii) mutant oligonucleotide mixed with the mutant template. In the other two cases no triplex formation was detected.
- the former cases correspond to triplexes formed by the wild type and quadruple-mutant sequences, while the latter cases reflect potential triplexes in both double mutants.
- FIG. 3 illustrates that a circular single-stranded DNA template containing the 5'-half of the pyrimidine-rich strand of the wild type sequence was obtained. Different triplex-forming oligonucleotides were annealed to this template. In the case of A, only the complementary duplex forming oligonucleotide was added.
- D is another
- DNA polymerases showed that DNA triplexes block elongation of different DNA polymerases. YR.R triplexes are favored under polymerization conditions (Baran ef al., 1991 ; Dayn ef al., 1992). Templates were circular pBluescript single-stranded DNAs carrying 18 nt-long homopyrimidine (FIG.
- FIG. 4A-C homopurine targets.
- Different oligonucleotides were added to form short Watson-Crick duplexes (FIG. 4A,D), hypothetical Hoogsteen duplexes (FIG. 4E), orthodox intermolecular triplexes (FIG. 4B,F), or H-like triplexes formed by a purine-rich hai ⁇ in and its homopyrimidine target (FIG. 4C). All triplexes were built from CG.G and TAT base triads (Samadashwily ef al., 1993).
- triplexes appear to be more stable than orthodox YR.R triplexes that consist of CG.G and TA.A triads (Beal and Dervan, 1991).
- YR.R triplexes consist of CG.G and TA.A triads (Beal and Dervan, 1991).
- oligonucleotides serving as primers for DNA polymerization, their 3'-ends were blocked by a 3' amino group (Nelson ef al., 1989).
- a standard "reverse" primer was annealed to all these templates and the pattern of DNA polymerization was analyzed by DNA sequencing or primer extension.
- T7 DNA polymerase (Sequenase®) was completely blocked by short triplexes within single-stranded templates (Samadashwily et al., 1993). Methods: 0.5 ⁇ g of single-stranded DNAs were mixed with 100-200 pmol of TFOs and incubated in Sequenase® Buffer (40 mM Tris HCI pH 7.5/ 50 mM NaCI/ 20 mM MgCI.) for 15 min. at 37°C. 15 pmol of the "reverse"
- Triplexes do lead to the premature termination of polymerization which is reflected by strong stop signals in all four sequencing ladders.
- Taq polymerase has a 5'-exonuclease activity on the non-template strand (Longley et al., 1990), which may contribute to triplex disruption and consequent cessation of termination.
- Taqf and Vent were compared. While both enzymes work under wide range of temperatures and ionic conditions, Vent lacks the 5'-exonuclease activity (Kong ef al., 1993).
- the pattern of primer extension by Taq and Vent polymerases was compared on a template with intermolecular triplexes (shown in FIG. 4B) under different Mg 2+ concentrations.
- Triplexes were formed in either Taq polymerase 2xPCR buffer (20 mM Tris HCI pH 9.0/ 100 mM KCI/ 5 mM MgCI./0.2% Triton X100) for 15 min at 37°C for thermophilic polymerases, or in modified Sequenase® buffer (5 mM MgCI./ 40 mM Tris HCI pH 7.5/ 50 mM NaCI) for 15 min at room temperature for Sequenase®. Primer extensions were performed as follows: labeling was done as in Fig. 3 for Taq and Vent polymerases or as in Fig.
- Triplexes within single-stranded templates were preformed at low (2.5 mM) Mg J+ , followed by DNA labeling under the same conditions, while
- Termination efficiency was compared while increasing the polymerization time from the standard 3-5 min. period up to 30 min. Even a 10 fold increase in polymerization time didn't change the termination pattern for the wild type sequence, suggesting that DNA polymerization
- thermophilic enzymes The influence of triplexes of different configurations on the activity of both thermophilic enzymes at 65°C was compared. While intermolecular
- duplex-to-single strands because short duplexes do not influence
- SSB protein does not interfere with TFO-caused termination. Strong inhibition of DNA polymerases by TF09 in vitro suggest TFOs are effective in blocking DNA replication in vivo also.
- the actual replication fork contains not only DNA polymerase but a complex of replication proteins, including helicases, SSB proteins, primases, topoisomerases, and the like (reviewed in Kornberg and Baker, 1992). Inhibition of the DNA-helicase activity of the SV40 T-antigen by TFOs were reported by Peleg and Manor (1993). The influence of the E.coli SSB protein on DNA synthesis of triplex-containing templates was investigated by comparing
- Sequenase® T7 DNA polymerase was used for primer extension in these experiments, because the E.coli SSB protein can substitute for the T7 SSB in a reconstituted replication system of phage T7 (Nakai and Richardson, 1988).
- Triplexes were preformed in Sequenase® buffer (10 mM Mg ,+ ) at 37°C.
- a primer was labeled with Sequenase® and then elongation was carried out at different concentrations of SSB.
- SSB helps DNA polymerase to overcome a triplex barrier, but its efficiency dramatically depends on the structure of the triplex.
- the loop may serve as a nucleus for SSB binding, and subsequent cooperative interaction between SSB molecules would cause complete dissociation of the complex.
- Intermolecular triplexes are resistant to SSB because they do not contain single-stranded regions.
- H-like TFOs are the strongest inhibitors of DNA polymerization in vitro, a possibility existed that they may be inefficient as DNA binding drugs in vivo, because the corresponding triplexes could be easy targets for SSB. Because SSB interacts with the sugar-phosphate backbone of DNA (Ruyechan and Wetmur, 1976), joining the two halves of the TFO with a non-sugar-phosphate linker may solve this problem. Influence of triplexes on the Initiation of DNA polymerization
- TFOs sometimes stop polymerization not only prior to the target sequence, but also immediately after it.
- a triplex may be formed behind the DNA polymerase just as it passes a target sequence.
- DNA templates used to analyze the efficiency of DNA synthesis are presented in FIG. 5.
- Either homopyrimidine (5 A-C) or homopurine (5 D-F) oligonucleotides complementary to the target sequences served as primers. These primers were annealed to the templates alone (5 A,D), in the presence of a purine-rich TFO (5 B,E), or in the presence of a mutant TFO (5 C,F) which lacks triplex-forming ability due to two G-to-T transversion (Samadashwily ef al., 1993).
- Templates 5B and 5E are similar in that the primer is a component of the triplex.
- the homopyrimidine primer is involved in only Watson-Crick (Watson-Crick) base pairing, while the homopurine primer participates in both Watson- Crick and Hoogsteen base pairing.
- TFO dramatically (at least ten fold) reduces the efficiency of DNA synthesis. All polymerization signals are very weak, showing that the first labeling step was affected. The mutant TFO does not influence DNA synthesis. This clearly indicates that triplex-formation is responsible for the indigent priming of polymerization. There are no apparent differences between the two
- primers used so primers within a triplex are generally inaccessible for the DNA polymerase.
- TFO prevents the DNA polymerase from recognizing a primer by forming a complex with it. This is most likely due to profound differences between double- and triple-helical DNA structures. In the cases described above, the 3 '-ends of the primers were at the boundary of the triple-helical stretch.
- Target DNA choices axe enlarged by use of alternate or non-natural oligonucleotides.
- Alternate strand oligonucleotides are constructed by choosing bases that match alternate strands of DNA, e.g.:
- Non-natural bases that form Hoogsteen's bonding with C and T include pseudocytosine.
- uracil replaces thymine (U* * -T).
- Example 1 Inhibition of the Polymerase Chain Reaction (PCR) By Triplex-Forming Oligonucleotides For Detection of Oncogene Mutations in Tumors.
- PCR Polymerase Chain Reaction
- TFOs triplex-forming oligonucleotides
- the protocol uses: (i) the Stoffel fragment of Taq polymerase which lacks exonuclease activity affecting triplex stability and works at high magnesium concentrations;
- Point mutations were found within a target sequence which make triplex formation unfavorable, reversing the inhibition of PCR amplification.
- the approach is suitable for inhibition of natural oncogenes, e.g., the ras oncogenes.
- the products of the highly conserved ras gene family play a pivotal role in signal transduction and regulation of cellular proliferation.
- Mutations within these genes occur in many tumor cells obtained in vitro or from natural tumors. Mutations within N-ras, c-Ki-ras and Ha-ras were detected in as many as 30% of human tumors (Bos, 1988). Remarkably, the vast majority of these mutations are clustered within a short segment
- TFOs would indicate that the gene is normal, while the appearance of such a product leads to the inference of the existence of mutations within oncogenes.
- GGT repeats from different ras oncogenes are cloned by techniques known to those of skill in the art (presented in FIG. 7) into the pBluescript plasmid.
- the efficiency of PCR amplification of those sequences is determined in the absence (control) or presence of TFOs.
- Optimal conditions i.e., ionic strength, temperature, TFOs concentrations and the like are determined based on complete blockage of amplification.
- Mutated versions of ras genes are synthesized and cloned using the known mutations observed in human tumors (reviewed in Bos, 1988). These mutants are amplified in the same conditions in the presence of TFOs to determine that PCR will proceed efficiently.
- Example 2 Inhibition of Replication of the Herpes Simplex Virus 1.
- HSV-1 is responsible for a variety of skin lesions and other infections. He ⁇ es virus infections represent a serious health problem in
- the genome of this virus has a number of homopurine-homopyrimidine sequences that are targeted by TFOs to block viral replication.
- Target 1 is in exon 3 of IR110 at the position 122558-122593:
- Target 2 is a 185-bp-long stretch located within the inverted repeat (IR-L) at the positions 117156-117341.
- TFO (i) and (ii) are very long targets. Because target 2 is a very long target, the combination of TFO (i) and (ii) is preferred to achieve higher specificity.
- HBV is a serious health problem worldwide. Chronic carriers of HBV reach almost 10% of some populations, and chronic hepatitis and cirrhosis are major causes of mortalities in those cases. It is also commonly accepted that HBV is involved in the development of hepatocellular
- Target 1 is within the P-gene of the virus (at the position 2670-2681): 5'-GAGAAAAGAAGA-3' 3'-CTCTTTTCTTCT-5'
- Target 2 is within the C-gene of the virus (at the position 2037-2048): 5'-CTTCTTTCCTTC-3'
- Target 3 is within the regulatory area of the virus responsible for the activation of gene expression and reverse transcription (at the position
- TFOs are: 5'-AGAGGAGGGGG-GAGGAGGG-3' or 5 '-TGTGGTGGGGG-GTGGTGGG-3 ' , where dashes correspond to abasic linkers incorporated into the TFO opposite thymines in the homopurine strand of the target.
- Example 4 Inhibition of the Papilloma virus.
- Papilloma virus is the major cause of cervical cancer, the most common malignancy in the developing world and in some populations in the U.S. Different strains of the human papilloma virus contain the same homopurine-homopyrimdine sequence which could be targeted by TFOs to prevent viral replication and cancer development.
- Target 1 is located within the protein-coding sequence ORF-Ec (at the position 436-452 in HPV57 and 438-452 in HPV2). 5'-GGGAGGAGAAGGAGG-3' 3'-CCCTCCTCTTCCTCC-5'
- TFOS 5'-GGAGGAAGAGGAGGG-3' or 5'-GGTGGTTGTGGTGGG-3'
- RecA protein, and E.coli single-strand DNA binding protein were obtained from the United States Biochemical. Restriction enzymes and enzymes for end-labeling of DNA were obtained from the Bethesda Research Laboratories.
- Oligonucleotides were synthesized on ABI High Throughput
- Biosystems They were deprotected by incubation in a concentrated ammonium hydroxide for 15 hours at 55°C, followed by concentrating in a
- oligonucleotides that cannot serve as substrates for DNA polymerases (FIG.6), a primary aliphatic amine was introduced at their 3' terminal nucleotides. This was done by an automatic conventional solid phase DNA synthesis using a 3' Amine-ON CPG prepacked column (Cruachem) which transfers a primary amine to the 3' terminus of a synthesized oligonucleotide without changing any chemistry or adding extra steps. Oligonucleotides may also be produced within a cell, for example, by recombinant technology. These intracellular oligonucleotides can then act on DNA replicating within the cell, or be extracted from the cell for use elsewhere.
- helper phage After 2 hours of incubation at 37°C, kanamycin was added up to 70mg/ml and cultures were subsequently incubated for 16 hours with vigorous aeration. Phage particles were separated from cells by centrifugation at 17,000 g for 10 min. followed by precipitation with 4% PEG in 0.7 M NH « CH,COO. Phage particles were resuspended in 300 ml H,0, and DNA was isolated by phenol-chloroform extraction followed by ethanol precipitation. DNA was rinsed with 70% ethanol and diluted in 60 ml of H,0.
- Single-stranded DNAs containing the purine- or pyrimidine-rich strand of the original and mutated sequences were isolated as described above. 0.8 mg of single-stranded DNA was then mixed with 1.2 mg of the corresponding double-stranded DNA, linearized by Sstl. A strand transfer reaction was carried out by 4.4 mg of RecA protein in 480 ml of 5% glycerol, 1mM DTT, 25 mM tris-HCI (pH 7.2), 10 mM MgCI. for 10 min. at 37°C. E. coli SSB protein and ATP were added up to 61 mM and 4mM, respectively, and incubation continued for another 30 min.
- nicked DNA was dissolved in 10 ml of IxSequenase® buffer (U.S. Biochem.) and labeled in the presence of 1 ml 0.1 M DTT, 1 ml a- ⁇ P-dATP (3000 Ci/mmol, Amersham), 2 ml labeling mix (U.S. Biochem.)
- oligonucleotides There are many methods of delivery (administration) of oligonucleotides into an organism. These methods include direct intravenous injection of oligonucleotides and delivery via liposome encapsulation.
- antibody-targeted small cell For directed delivery to specific targets, antibody-targeted small cell
- liposomes may be used (Leserman, etal., 1994). Advantages of liposome delivery compared to use of oligonucleotides free in solution include protection against degradation, reduction of toxicity (if any), improved pharmacokin ⁇ tics, and, possibly, increased intracellular transport.
- Liposome size and composition the nature of the encapsulated molecule, the type of liquid used for targeting and its linkage to the liposome, as well
- cationic liposomes successfully delivered antisense oligonucleotides to cells infected by human papillomavirus (Lappalainen, ef al., 1994) and antisense oligonucleotides in antibody-targeted liposomes (immunoliposomes) bound
- Retroviral infection appears to stimulate cellular uptake of oligonucleotide liposomes (Robert, ef al., 1993).
- oligonucleotides concentrations of oligonucleotides may be required as compared to delivery by liposomes (Leonetti, ef al., 1990).
- a suitable dose for systemic administration of oligonucleotides is 0.01-50 mg/kg once or twice a day
- Oligonucleotides may be inco ⁇ orated into a earner, e.g., a polyethylene oxide-polypropylene oxide copolymer (Dekeyser, ef al. , 1993).
- a earner e.g., a polyethylene oxide-polypropylene oxide copolymer (Dekeyser, ef al. , 1993).
Abstract
L'invention concerne des oligodésoxyribonucléotides de conception spécifique formant des triplex dans l'ADN monobrin ou double-brin sur des cibles homopurine-homopyrimidine. Ces triplex bloquent in vitro la synthèse de l'ADN par tous les ADN polymérases étudiées, y compris Sequenase®, Taq, Vent et Pol I. Un phénomène analogue se produit lorsque les ADN polymérases sont complétées par des protéines de réplication secondaire, y compris la protéine fixatrice d'ADN simple-brin. Le blocage de réplication est éminemment spécifique des séquences, et même un ou deux points de substitution dans la séquence cible où l'oligonucléotide interrompt le processus. Le blocage spécifique des séquences de la réplication d'ADN in vivo est facilité par les méthodes et les compositions décrites dans cette invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35808994A | 1994-12-15 | 1994-12-15 | |
US08/358,089 | 1994-12-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1996018732A2 WO1996018732A2 (fr) | 1996-06-20 |
WO1996018732A9 true WO1996018732A9 (fr) | 1996-10-03 |
WO1996018732A3 WO1996018732A3 (fr) | 1997-02-13 |
Family
ID=23408267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/016368 WO1996018732A2 (fr) | 1994-12-15 | 1995-12-14 | Inhibition specifique des sequences de la synthese de l'adn a l'aide d'oligonucleotides formant des triplex |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1996018732A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6914137B2 (en) | 1997-12-06 | 2005-07-05 | Dna Research Innovations Limited | Isolation of nucleic acids |
JP4220744B2 (ja) | 2001-09-25 | 2009-02-04 | 株式会社アイシン・コスモス研究所 | ライゲーション阻害を用いてライブラリーを加工する方法 |
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US7498315B2 (en) | 2004-06-01 | 2009-03-03 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US7807647B2 (en) | 2004-06-01 | 2010-10-05 | Pronai Therapeutics, Inc. | Methods and compositions for cancer therapy |
WO2007064857A2 (fr) | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Formulation de liposomes amphoteres |
WO2023187394A1 (fr) * | 2022-03-31 | 2023-10-05 | The University Court Of The University Of Edinburgh | Expression génique contrôlable |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL103311A0 (en) * | 1991-10-07 | 1993-03-15 | Univ Johns Hopkins | Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers |
WO1994017086A1 (fr) * | 1993-01-25 | 1994-08-04 | Apollon, Inc. | Regulation de genes par ciblage d'une helice triple intramoleculaire potentielle |
-
1995
- 1995-12-14 WO PCT/US1995/016368 patent/WO1996018732A2/fr active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6150339A (en) | Anti-viral guanosine-rich oligonucleotides | |
Kool | Circular oligonucleotides: new concepts in oligonucleotide design | |
Samadashwily et al. | Suicidal nucleotide sequences for DNA polymerization. | |
US5624824A (en) | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence | |
Lee et al. | Transcription pausing by Escherichia coli RNA polymerase is modulated by downstream DNA sequences. | |
Frank-Kamenetskii et al. | Triplex DNA structures | |
US5728521A (en) | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence | |
Praseuth et al. | Triple helix formation and the antigene strategy for sequence-specific control of gene expression | |
Boiziau et al. | Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism | |
US6057153A (en) | Stabilized external guide sequences | |
US5849900A (en) | Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids | |
AU4699696A (en) | Stabilized external guide sequences | |
JP2005522997A (ja) | 交代セグメントを含むオリゴヌクレオチド及びその用途 | |
EP0759979A1 (fr) | Inhibition par oligonucleotides antisens du virus de l'hepatite c | |
HU215187B (hu) | Eljárás az RNS funkcióját gátló genetikai egységek előállítására, és eljárás sejtekbe való bevitelükre | |
WO1994007367A9 (fr) | Oligomeres antiviraux liant des voies de polypurine d'arn monocatenaire ou d'hybrides d'arn-adn | |
Praseuth et al. | Peptide nucleic acids directed to the promoter of the α-chain of the interleukin-2 receptor | |
Skoog et al. | Repression of bacteriophage promoters by DNA and RNA oligonucleotides | |
WO1996018732A9 (fr) | Inhibition specifique des sequences de la synthese de l'adn a l'aide d'oligonucleotides formant des triplex | |
WO1996018732A2 (fr) | Inhibition specifique des sequences de la synthese de l'adn a l'aide d'oligonucleotides formant des triplex | |
Ts et al. | Nonionic Oligonucleotide Analogs (Matagen™) as Anticodic Agents in Duplex and Triplex Formation | |
Hélène et al. | Sequence‐Specific Control of Gene Expression by Antigene and Clamp Oligonucleotides | |
JP4516643B2 (ja) | ヌクレオチド配列の間の交換を促進するためのカチオン性高分子調製物 | |
EP2327784A2 (fr) | Acides nucléiques pour inhiber l'expression de la protéine Hairless et méthodes d'utilisation | |
US6682930B1 (en) | Triplex forming oligonucleotides and their use in anti-HBV |